Compounds > sr141716
Page last updated: 2024-08-26

sr141716 and Compensatory Hyperinsulinemia

sr141716 has been researched along with Compensatory Hyperinsulinemia in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bajza, A; Literáti-Nagy, B; Literati-Nagy, Z; Mandl, J; Szilvássy, Z; Tory, K; Vígh, L1
Galzin, AM; Guillot, E; Lacombe, A; Lefèvre, AL; Magnan, C; Migrenne, S; Pruniaux, MP1
Delafoy-Plasse, L; Delion, V; Duvivier, VF; Galzin, AM; Guillot, E; Le Bail, JC; Lechevalier, P; Pruniaux, MP1
Chen, D; Liu, X; Shi, Y; Zhang, W1
Bensaid, M; Esclangon, A; Gary-Bobo, M; Le Fur, G; Maffrand, JP; Oury-Donat, F; Soubrié, P1

Other Studies

5 other study(ies) available for sr141716 and Compensatory Hyperinsulinemia

ArticleYear
Synergic insulin sensitizing effect of rimonabant and BGP-15 in Zucker-obese rats.
    Pathology oncology research : POR, 2013, Volume: 19, Issue:3

    Topics: Analysis of Variance; Animals; Blood Glucose; Disease Models, Animal; Drug Synergism; Glucose; Glucose Clamp Technique; Hyperinsulinism; Insulin; Insulin Resistance; Male; Obesity; Oximes; Piperidines; Pyrazoles; Rats; Rats, Zucker; Rimonabant

2013
Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2009, Volume: 296, Issue:4

    Topics: Adiponectin; Animals; Anti-Obesity Agents; Dietary Fats; Disease Models, Animal; Eating; Glucose; Glucose Tolerance Test; Hyperinsulinism; Insulin; Insulin Resistance; Intra-Abdominal Fat; Lipids; Liver; Male; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Rimonabant; Subcutaneous Fat; Weight Loss

2009
Beneficial effect of a chronic treatment with rimonabant on pancreatic function and beta-cell morphology in Zucker Fatty rats.
    European journal of pharmacology, 2009, Aug-15, Volume: 616, Issue:1-3

    Topics: Animals; Body Weight; Cannabinoid Receptor Modulators; Cattle; Eating; Fasting; Glucose; Glucose Tolerance Test; Homeostasis; Hyperinsulinism; Hyperplasia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Pancreas; Piperidines; Pyrazoles; Rats; Rats, Zucker; Rimonabant; Time Factors

2009
Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Adiposity; AMP-Activated Protein Kinases; Animals; Diet; Dyslipidemias; Energy Metabolism; Enzyme Activation; Gene Silencing; Gene Targeting; Glucose Intolerance; Hyperinsulinism; Hyperphagia; Hypothalamus; Mice; Mice, Inbred C57BL; Obesity; Phosphorylation; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, G-Protein-Coupled; Rimonabant; Weight Loss

2012
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.
    Molecular pharmacology, 2003, Volume: 63, Issue:4

    Topics: 3T3 Cells; Adipocytes; Adiponectin; Adipose Tissue; Animals; Body Weight; Cannabinoids; Cells, Cultured; Disease Models, Animal; Gene Expression; Hyperinsulinism; Intercellular Signaling Peptides and Proteins; Male; Mice; Obesity; Piperidines; Protein Biosynthesis; Proteins; Pyrazoles; Rats; Rats, Zucker; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; RNA, Messenger

2003